Sat, Jul 26, 2014, 12:16 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

  • badlands57078 badlands57078 Jul 2, 2013 3:23 AM Flag

    INSM's future

    Insmed is a more stable company today than ever. No other product in its history has advanced this far. Now there is fast track, QIDP, relatively successful phase 3 and WL, who I am told made another purchase today. Bench players are solid. Gupta did a fine job on the CC.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Badlands, that is not entirely correct. Insmed does have and FDA approved drug that currently is not marketed because of patent infringement some years ago. Below is something the FDA wrote in March 2009

      FDA Position on Allowing Patients with ALS Access to Iplex under an IND
      Today, the Food and Drug Administration is sharing with the public its decision to allow patients with Amyotrophic Lateral Sclerosis, a fatal neurodegenerative disease also known as Lou Gehrig’s Disease, or ALS, to have access to a drug called Iplex under an Investigational New Drug (IND) application. Iplex (mecasermin rinfabate [rDNA origin] injection), is a combination of two substances: human insulin-like growth factor 1 (IGF-1) and human insulin-like growth factor-binding protein-3 (rhIGFBP-3). Iplex is approved by the FDA only for the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. The drug is currently not marketed because of a court order related to patent infringement. Iplex is made by Insmed, a biologics company headquartered in Richmond, Virginia.

    • Given the competitive and regulatory risks that continue to surround Insmed, however, only biotech-savvy Fools should even consider buying into that optimism.

    • Fact WL bought:

      Transaction
      & Date Reported
      Date Company Symbol Insider
      Relationship Shares
      Traded Average
      Price Total
      Amount Shares
      Ownership Filing
      2013-07-01
      Purchase 2013-07-01
      8:50 pm INSMED INC INSM Lewis William
      (President and CEO) 7,585 $9.828 $74,547 41,739
      (Direct) View

      Sentiment: Strong Buy

 
INSM
17.50-0.11(-0.62%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.